Ascelia Pharma
Biotechnology company developing and commercializing novel drugs for orphan oncology.
ACE | ST
Overview
Corporate Details
- ISIN(s):
- SE0010573113 (+2 more)
- LEI:
- 5493002YR9VCJJPWYN08
- Country:
- Sweden
- Address:
- Hyllie Boulevard 34, 215 32 Malmö
- Website:
- https://www.ascelia.com/
- Sector:
- Manufacturing
Description
Ascelia Pharma is a biotechnology company focused on developing and commercializing novel drugs for orphan oncology. The company aims to address unmet medical needs for patients with rare cancer conditions. Its lead product candidate, Orviglance, is an oral manganese-based contrast agent for magnetic resonance imaging (MRI). It is designed to improve the detection and visualization of liver metastases, particularly in adult patients with severely impaired kidney function for whom existing contrast agents may be contraindicated. The company's strategy involves identifying, developing, and commercializing innovative treatments for niche cancer-related conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-11-07 07:30 | English | 4.2 MB | |||
| 2024-10-30 14:45 |
Kommuniké från extra bolagsstämma den 30 oktober 2024 i Ascelia Pharma AB
|
Swedish | 188.8 KB | ||
| 2024-10-04 15:48 |
Notice of Extraordinary General Meeting in Ascelia Pharma AB
|
English | 205.3 KB | ||
| 2024-10-04 15:48 |
Kallelse till extra bolagsstämma i Ascelia Pharma AB
|
Swedish | 204.4 KB | ||
| 2024-10-04 15:25 |
Ascelia Pharma Announces Proposal for Election of Marianne Kock as New Member o…
|
English | 190.9 KB | ||
| 2024-09-30 22:30 | Swedish | 13.7 KB | |||
| 2024-09-30 15:56 | Swedish | 14.8 KB | |||
| 2024-09-30 15:25 |
Change in Number of Shares and Votes in Ascelia Pharma AB
|
English | 188.3 KB | ||
| 2024-09-25 10:40 | English | 36.1 KB | |||
| 2024-09-13 13:25 |
Ascelia Pharma beslutar om en riktad emission av konvertibler om 7,5 MSEK
|
Swedish | 200.0 KB | ||
| 2024-09-05 17:20 |
Ascelia Pharma offentliggör slutligt utfall i fulltecknad företrädesemission om…
|
Swedish | 208.8 KB | ||
| 2024-09-05 17:20 |
Ascelia Pharma Announces Final Outcome in Fully Subscribed SEK 105 Million Righ…
|
English | 208.7 KB | ||
| 2024-09-04 07:30 |
Ascelia Pharma offentliggör preliminärt utfall i företrädesemission
|
Swedish | 199.8 KB | ||
| 2024-09-04 07:30 |
Ascelia Pharma Announces Preliminary Outcome in Rights Issue
|
English | 199.5 KB | ||
| 2024-08-16 14:44 |
Ascelia Pharma Announces Prospectus in Connection with Rights Issue
|
English | 203.7 KB |
Automate Your Workflow. Get a real-time feed of all Ascelia Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Ascelia Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Ascelia Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-22 | Marie Birgitta Källström | Other | Other | 18,752 | 40,316.80 SEK |
| 2025-04-15 | Niels Mengel | Other | Other | 92,304 | 198,453.60 SEK |
| 2025-04-15 | Peter Benson | Other | Other | 50,000 | 107,500.00 SEK |
| 2025-04-15 | Carin Linde | Other | Other | 40,328 | 86,705.20 SEK |
| 2025-04-15 | Peter Benson | Other | Other | 21,688 | 46,629.20 SEK |
| 2025-04-15 | Peter Benson | Other | Other | 20,472 | 44,014.80 SEK |
| 2025-04-15 | Julie Brogren | Other | Other | 18,000 | 38,700.00 SEK |
| 2025-04-15 | Peter Benson | Other | Other | 6,152 | 13,226.80 SEK |
| 2024-09-03 | KIBEGEON | Other | Sell | 913,545 | 150,917.63 SEK |
| 2024-09-03 | Niels Mengel | Other | Sell | 131,965 | 17,815.28 SEK |
Peer Companies
